Abstract: A mutein recombinant adenosine deaminase having any oxidizable cysteine residue replaced by a non-oxidizable amino acid residue is disclosed. Stabilized recombinant adenosine deaminase, polymer conjugates and methods of treatment using the same are also disclosed.

Abstract: Connector which provide conduits between a sealed environment and an exterior of the environment includes a housing, a plurality of internal conduits extending from a first side of the housing, each adapted to communicate with a respective sampling device situated in the sealed environment, and a single external conduit extending from a second side of the housing opposite the first side and adapted to communicate with a measurement device exterior of the sealed environment. The housing is constructed to enable each internal conduits to alternatingly align with the external conduit such that each sampling device is able to communicate with the measurement device. By providing a connector which is able to provide a flow passage between multiple sampling devices and a single measurement device, at different times, it is not necessary to enter the sealed environment in order to configure a single sampling device in communication with the measurement device.

Abstract: The present invention provides polymeric delivery systems including a multi-substituted aromatic moiety. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.

Abstract: The present invention provides polymeric delivery systems including an aromatic allyllic acyl group. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.

Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.

Abstract: Vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are hydrolysis resistant in vitro, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed.

Abstract: A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, is disclosed. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.

Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.

Abstract: A method of treating a resistant or refractory cancer in a mammal includes administering an effective amount of a compound of to the mammal. In preferred aspects, the cancer is resistant or refractory to CPT-11 or CPT therapy.

Abstract: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.

Abstract: Provided are methods for treating an adenosine deaminase-mediated pulmonary disease such as asthma, pulmonary fibrosis, cystic fibrosis and chronic obstructive pulmonary disease in a mammal in need thereof, by administering and effective amount of a polymer-conjugated adenosine deaminase.

Abstract: The present invention relates to polymer conjugates of SS1P, and methods of making using the same.

Abstract: A process for efficiently preparing polymer conjugates such as branched PEG-polypeptide conjugates, in large scale without column chromatography clean up of the activated PEG linkers to remove impurities is disclosed.

Abstract: Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed. One preferred compound is Methods of making and using the compounds and conjugates described herein are also provided.

Abstract: Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed. One preferred compound is Methods of making and using the compounds and conjugates described herein are also provided.

Abstract: The present invention is directed to methods of preparing linear polymers such as polyalkylene oxides containing a terminal amine in high purity. One preferred method includes reacting a polyalkylene oxide such as polyethylene glycol containing a terminal azide with a phosphine-based reducing agent such as triphenylphosphine or an alkali metal borohydride reducing agent such as sodium borohydride in a solvent to reflux. The resultant polymer-amines are of sufficient purity so that expensive and time consuming purification steps required for pharmaceutical grade polymers are avoided.

Abstract: A new nucleic acid molecule that is codon-optimized to express beta interferon in Escherichia coli with greater efficacy.

Abstract: Methods of preparing vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are preferably releasable, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed.

Abstract: The present invention is directed to methods of preparing linear polymers such as polyalkylene oxides containing a terminal amine in high purity. One preferred method includes reacting a polyalkylene oxide such as polyethylene glycol containing a terminal tosylate with a protected amine salt to form a polymer containing a terminal protected amine and thereafter deprotecting the polymer containing the terminal protected amine to form the polymer having a terminal amine. The resultant polymer-amines are of sufficient purity so that expensive and time consuming purification steps required for pharmaceutical grade polymers are avoided.

Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.